Evidence map›Paper›PMID 30097825›Full record

ArticleJournal of neuro-oncology2018

Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study.

Taeryool Koo, Do Hoon Lim, Ho Jun Seol, Yun-Sik Dho, Il Han Kim, Jong Hee Chang, Jeongshim Lee, Tae-Young Jung, Ho-Shin Gwak, Kwan Ho Cho and 13 more

Open access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

Taeryool KooDepartment of Radiation Oncology, Hallym University Sacred Heart Hospital, Anyang, South Korea.
Do Hoon LimDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Ilwon-Ro, Gangnam-Gu, Seoul, 06351, South Korea. dh8lim@skku.edu.ORCID http://orcid.org/0000-0002-5426-0604
Ho Jun SeolDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Yun-Sik DhoDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea.
Il Han KimDepartment of Radiation Oncology, Seoul National University College of Medicine, Seoul, South Korea.
Jong Hee ChangDepartment of Neurosurgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Jeongshim LeeDepartment of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Tae-Young JungDepartment of Neurosurgery, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Ho-Shin GwakDepartment of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea.
Kwan Ho ChoProton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, South Korea.
Chang-Ki HongDepartment of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Ik Jae LeeDepartment of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
El KimDepartment of Neurosurgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
Jin Hee KimDepartment of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
Yong-Kil HongDepartment of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Hong Seok JangDepartment of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Chae-Yong KimDepartment of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
In Ah KimDepartment of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Sung Hwan KimDepartment of Radiation Oncology, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea.
Young Il KimDepartment of Radiation Oncology, Chungnam National University School of Medicine, Daejeon, South Korea.
Eun-Young KimDepartment of Neurosurgery, Inha University Hospital, Inha University of Medicine, Inchon, South Korea.
Woo Chul KimDepartment of Radiation Oncology, Inha University Hospital, Inha University of Medicine, Inchon, South Korea.
Semie HongDepartment of Radiation Oncology, Konkuk University Medical Center, School of Medicine, Konkuk University, Seoul, South Korea.
Yonsei University · KRKeimyung University Dongsan Medical Center · KRSeoul National University · KRNational Cancer Center · KRSamsung Medical Center · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRChonnam National University Hwasun Hospital · KRChungnam National University · KRHallym University Sacred Heart Hospital · KRInha University Hospital · KRKonkuk University Medical Center · KRSeoul National University Bundang Hospital · KRThe Catholic University of Korea St. Vincent's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOptimal treatment strategies for low-grade glioma (LGG) remain controversial. We analyzed treatment outcomes and evaluated prognostic factors of adult LGG patients in Korea.

methodsWe reviewed the medical records of 555 patients diagnosed with WHO grade II LGG (astrocytoma 37.8%, oligoastrocytoma 15.3%, and oligodendroglioma 46.8%) at 14 institutions between 2000 and 2010. Primary and secondary endpoints were progression-free survival (PFS) and overall survival (OS). Propensity-score matching (PSM) analyses were performed to correct imbalances in patient/tumor characteristics among adjuvant treatment groups.

resultsThe median follow-up time was 83.4 months, and the 5-year PFS and OS rates were 52.2% and 83.0%, respectively. Male, older age, poorer performance status, multiple lobe involvement, and astrocytoma histology were associated with poorer survival. Among the treatment factors, gross total resection (GTR) was associated with better PFS and OS, and adjuvant chemotherapy with improved PFS. Interestingly, adjuvant radiotherapy (RT) did not improve PFS; rather, it was related with poorer OS. Regarding patient/tumor characteristics, the RT group had poorer characteristics than the non-RT group. After PSM, we detected a tendency for improved PFS in the matched RT group, and no significant difference in OS compared with the matched non-RT group.

conclusionsThe achievement of GTR is important to improve survival in LGG patients. Adjuvant chemotherapy may enhance PFS, but adjuvant RT did not improve survival outcomes. After PSM, we observed potential impacts of adjuvant RT on PFS. Our results may reflect real-world practice and consequently may help to optimize treatment strategies for LGG.

Indexed as

AdultAgedBrain NeoplasmsChemotherapy, AdjuvantFemaleFollow-Up StudiesGliomaHumansMaleMiddle AgedNeoplasm GradingPrognosisRadiotherapy, AdjuvantRepublic of KoreaAdjuvant treatmentChemotherapyLow-grade gliomaRadiotherapySurvival

Identifiers

PMID30097825
OpenAlexW2885539871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.